Abstract
BackgroundImmunocytokines are promising new therapeutic approaches to enhance T-cell response by delivering interleukins into the tumoral site. Fusion of wild-type or attenuated interleukins to anti-PD-1 antibody has shown some efficacy...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have